Holen Sie sich die Stockscreener-App
30.73
0.49%
0.15
Schlusskurs vom Vortag:
$30.58
Offen:
$30.66
24-Stunden-Volumen:
582.93K
Relative Volume:
0.57
Marktkapitalisierung:
$2.41B
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-258.76M
KGV:
-7.889
EPS:
-3.8953
Netto-Cashflow:
$-213.66M
1W Leistung:
-1.95%
1M Leistung:
-10.17%
6M Leistung:
+18.56%
1J Leistung:
+50.86%
1-Tages-Spanne:
$30.65
$31.22
1-Wochen-Bereich:
$29.27
$31.98
52-Wochen-Spanne:
$18.55
$35.79
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
30.73 | 2.40B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Barclays | Underweight → Overweight |
| 2026-03-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $38 to $67 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan
Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Eastern Progress
Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup - ChartMill
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - Yahoo Finance
State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics - Stock Titan
The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones - Sahm
LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - Sahm
Celldex (CLDX) Receives a Buy from Barclays - The Globe and Mail
Celldex Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Celldex: Q1 Earnings Snapshot - theheraldreview.com
MSN Money - MSN
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex filled two late-stage hives trials 6 months early - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) widens loss while funding late-stage barzolvolimab trials - Stock Titan
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, Vs. FactSet Est of $795K - Moomoo
Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline - Stock Titan
Celldex Reports First Quarter Financial Results and Provides Corporate Update - ChartMill
Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX) - Seeking Alpha
FMR LLC reports 5.6% stake in CellDex Therapeutics (CLDX) - Stock Titan
Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com
Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com Australia
Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics announces public offering of common stock - MSN
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance
Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):